Загрузка...
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience
Pancreatic adenocarcinoma is the fourth leading cause of cancer death. Recently, MM-398 (nanoliposomal irinotecan) was shown to be associated with significant improvement in outcome measures with acceptable toxicities when combined with 5-fluorouracil (5-FU)/leucovorin (LV) compared to 5-FU/LV alone...
Сохранить в:
| Опубликовано в: : | Med Oncol |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4976592/ https://ncbi.nlm.nih.gov/pubmed/26995224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-016-0753-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|